دورية أكاديمية
Glycemic Control by Treatment Modalities: National Registry-Based Population Data in Children and Adolescents with Type 1 Diabetes
| العنوان: | Glycemic Control by Treatment Modalities: National Registry-Based Population Data in Children and Adolescents with Type 1 Diabetes |
|---|---|
| المؤلفون: | Šumnik, Zdenek, Pavlíková, Marketa, Neuman, Vit, Petruželková, Lenka, Konečná, Petra, Venháčová, Petra, Škvor, Jaroslav, Pomahačová, Renata, Neumann, David, Vosáhlo, Jan, Strnadel, Jiri, Kocourková, Kamila, Obermannová, Barbora, Šantová, Alzbeta, Plachý, Lukas, Průhová, Stepanka, Cinek, Ondrej |
| المصدر: | Hormone Research in Paediatrics ; volume 97, issue 1, page 70-79 ; ISSN 1663-2818 1663-2826 |
| بيانات النشر: | S. Karger AG |
| سنة النشر: | 2023 |
| الوصف: | Introduction: The aim of the study was to assess the differences in key parameters of type 1 diabetes (T1D) control associated with treatment and monitoring modalities including newly introduced hybrid closed-loop (HCL) algorithm in children and adolescents with T1D (CwD) using the data from the population-wide pediatric diabetes registry ČENDA. Methods: CwD younger than 19 years with T1D duration >1 year were included and divided according to the treatment modality and type of CGM used: multiple daily injection (MDI), insulin pump without (CSII) and with HCL function, intermittently scanned continuous glucose monitoring (isCGM), real-time CGM (rtCGM), and intermittent or no CGM (noCGM). HbA1c, times in glycemic ranges, and glucose risk index (GRI) were compared between the groups. Results: Data of a total of 3,251 children (mean age 13.4 ± 3.8 years) were analyzed. 2,187 (67.3%) were treated with MDI, 1,064 (32.7%) with insulin pump, 585/1,064 (55%) with HCL. The HCL users achieved the highest median TIR 75.4% (IQR 6.3) and lowest GRI 29.1 (7.8), both p < 0.001 compared to other groups, followed by MDI rtCGM and CSII groups with TIR 68.8% (IQR 9.0) and 69.0% (7.5), GRI 38.8 (12.5) and 40.1 (8.5), respectively (nonsignificant to each other). These three groups did not significantly differ in their HbA1c medians (51.8 [IQR 4.5], 50.7 [4.5], and 52.7 [5.7] mmol/mol, respectively). NoCGM groups had the highest HbA1c and GRI and lowest TIR regardless of the treatment modality. Conclusion: This population-based study shows that the HCL technology is superior to other treatment modalities in CGM-derived parameters and should be considered as a treatment of choice in all CwD fulfilling the indication criteria. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1159/000530833 |
| الإتاحة: | https://doi.org/10.1159/000530833Test https://karger.com/hrp/article-pdf/97/1/70/4163077/000530833.pdfTest |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test/ ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.CA55C1CF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1159/000530833 |
|---|